Harrow Faces Securities Probe After VEVYE Revenue Miss; Payer Pressure Materializes

What happened

Harrow disclosed that Q1 2026 VEVYE revenue of $20.9 million fell short of expectations due to an $8 million gross-to-net adjustment from new commercial coverage, prompting a law firm to investigate potential securities law violations. This marks the first concrete evidence that payer pressure—a key risk flagged in the DeepValue report—is materially impacting the company's flagship product. Despite strong overall revenue growth and improved operating cash flow in 2025, the miss underscores the fragility of Harrow's branded portfolio in the face of reimbursement headwinds. The investigation adds legal overhang to an already stretched balance sheet, with $250 million of 8.625% notes due 2030 and interest coverage below 1x. Management previously characterized VEVYE as a growth driver; this revelation challenges that narrative and raises questions about the sustainability of investor expectations.

Implication

The VEVYE miss and legal probe validate the DeepValue report's 'POTENTIAL SELL' stance and suggest the risk/reward has skewed decisively negative. Investors should reduce exposure until there is clear evidence that gross-to-net adjustments are stabilizing, free cash flow turns consistently positive, and the legal risk is resolved. Without a durable margin of safety, the equity is pricing in optimistic assumptions that are increasingly contradicted by hard data.

Thesis delta

The thesis shifts from a cautious 'POTENTIAL SELL' to a more confident SELL, as a previously identified key risk has materialized. The VEVYE revenue miss due to commercial coverage adjustments indicates that payer pressure is already eroding revenue quality, while the ensuing securities investigation adds a new layer of downside. Near-term catalysts are now dominated by legal and operational uncertainties, making the equity unattractive at current levels without visible de-risking.